Safety and immunogenicity of intradermal rabies vaccination for post exposure prophylaxis

Ravish S. Hardanahalli; Rachana R. Annadani; Madhusudana N. Shampur; Veena Vijayashankar; Ashwath Narayana H. Doddabele; Gangaboraiah .; Malatesh Undi

doi:10.18203/2394-6040.ijcmph20160634

Authors

Ravish S. Hardanahalli Department of Community Medicine, Kempegowda Institute of Medical Sciences, Banashankari II stage, Bangalore 70, Karnataka
Rachana R. Annadani Department of Community Medicine, SS Institute of Medical Sciences & Research Centre, Davangere, Karnataka
Madhusudana N. Shampur Department of Neurovirology, National Institute of Mental health and Neurosciences (NIMHANS), Hosur Road, Bangalore 560029, Karnataka
Veena Vijayashankar Department of Community Medicine, BGS Global Institute of Medical Sciences, Uttarahalli, Kengeri, Bangalore, Karnataka
Ashwath Narayana H. Doddabele Department of Community Medicine, Kempegowda Institute of Medical Sciences, Banashankari II stage, Bangalore 70, Karnataka
Gangaboraiah . Department of Community Medicine, Kempegowda Institute of Medical Sciences, Banashankari II stage, Bangalore 70, Karnataka
Malatesh Undi Department of Community Medicine, SS Institute of Medical Sciences & Research Centre, Davangere, Karnataka

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20160634

Keywords:

Animal bites, Intradermal rabies vaccination, Safety, Immunogenicity

Abstract

Background: The affordability to anti-rabies vaccine (ARV) for intramuscular administration in post exposure prophylaxis (PEP) is a major constraint. Therefore, in countries, where there are financial constraints, WHO recommends intradermal rabies vaccination (IDRV) that reduces the quantity and cost of vaccination.The aim of the study was to evaluate the safety and immunogenicity of IDRV implemented under National pilot project.

Methods:A longitudinal study was conducted at anti rabies clinic (Government referral hospital), India where IDRV is implemented. The study included 515 animal bite cases who received PEP as recommended by WHO. ARV was administered intradermally using updated Thai red-cross regimen.

Results: The incidence of adverse drug events was 9.7% and all resolved without any complication. The geometric mean concentration of rabies virus neutralizing antibodies among the vaccinees was 11.89IU/mL on day 14, which was above the WHO recommended titers of ≥ 0.5IU/mL.

Conclusions:IDRV was found to be safe and immunogenic in PEP.

Metrics

Metrics Loading ...

References

Weekly Epidemiological Record. World Health Organization (WHO) Rabies vaccines, WHO position paper. 2007;49/ 50(82):425-35.

WHO Expert Consultation on Rabies: Second report, Technical Report Series 982. WHO Geneva. 2013:54-5.

WHO Expert Consultation on Rabies: First Report, Technical Report Series 931. WHO Geneva. 2005;26-7.

Sudarshan MK, Mahendra BJ, Madhusudana SN, Ashwath Narayana DH, Rahaman A, Rao NSN. An epidemiological study of animal bites in India: results of a WHO sponsored national multi-centric rabies survey. J Commun Dis. 2006;38(1):32-9.

National guidelines for rabies prophylaxis and intradermal administration of cell culture rabies vaccines: National Institute of Communicable Diseases, Ministry of Health & Family welfare, New Delhi, India. 2007;14-5.

Madhusudana SN, Sanjay TV, Mahendra BJ, Suja MS: Simulated post-exposure rabies vaccination with purified chick embryo cell vaccine using a modified Thai Red Cross regimen. Int J Infect Dis. 2004;8(3):175-9.

Sudarshan MK, Madhusudana SN, Mahendra BJ, Ashwathnarayana DH, Anand Giri MS, Popova O. Evaluation of a new five injection, two site, intradermal schedule for purified chick embryo cell rabies vaccine: A randomized, open label active controlled trial in healthy adult volunteers in India. Current therapeutic research. 2005;66(4):323-4.

Sampath G, Suhasini VR, Lakshmiprasad RM, Udayabhaskara RY, Palaniappan C: An immunogenicity study of a newly introduced vero cell rabies vaccine (Abhayrab) manufactured in India. Vaccine. 2005;23(7):897-900.

Khawplod P, Tantawichien T, Wilde H, Limusanno S, Tantawichien T, Saikasem A. Use of Rabies vaccines after Reconstitution and Storage. Clin Infect Dis. 2002;34:404-6.

Suntharasamai P, Chaiprasithikul P, Wasi C, Supanaranond W, Auewarakul P, Chanthavanich P: A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for post exposure prophylaxis. Vaccine. 1994;12(6):508-12.